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SIX YEARS OF CARDIAC DATABASE MANAGEMENT: THE IMPACT ON CLINICAL
PRACTICE
Furnaz S
Aga khan university and Hospital, Karachi, Pakistan
OBJECTIVES: To assess the impact of database development on clinical practice
and quality of care.METHODS:We chose the following aspects of patient care to be
included in the database form: pre-surgery patient condition and medications,
surgery information, recovery information, status of the patient atdischarge, 30-
days and 365-days post-surgery follow-up information.Information was collected
through structured questionnaire and entered into Microsoft Access software.
RESULTS: From January 2006–May 2011, there was 3418 open heart surgeries per-
formed. The overall 30-daymortality was 3.6%. Post-surgery morbidity was
21.5%which includes 3.6% reoperation for bleeding 0.6% neurological 0.7% dialysis
1.3% heart failure 0.3% septicemia 1.8% prolonged ventilation 8.6%multiorgan fail-
ure and 0.9% respiratory complications 1.7% cardiac arrest,1.1% deep sternal
wound infection 0.1% Followup at30-days patients alivewere 91.6% death 0.1% lost
to follow-up 3.6%and 365-daysshowed that alive 93.2% death2.1% lost to
followup,4.6%.CONCLUSIONS:Before thisdatabase, therewasnoway tomonitor the
risk factors, mortality and morbidity. Fortunately with the development of database,
pre operation risk factors, post-surgery mortality and morbidity rates could easily be
generated. Based on the prevalent risk factors coming up in our data we can help
prevent the cardiac disease. It also helped in controlling preventable post-surgery
complications. It also helps in identification of a gap inpatient knowledge regarding
theuseofwarfarin afterheart valve surgery anddeficiencies in laboratory capabilities,
both causing catastrophic complications. As a result, we modified our practice in an
effort to address these issues and reduce the complication rates after heart valve
surgery.Updatedandstringentlymaintaineddatabasehelps to identifydeficiencies in
practice and provides a direction for future improvement.
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DAY OF WEEK OF PROCEDURE AND 30-DAY IN-HOSPITAL MORTALITY FOR
ELECTIVE SURGERY
Jen MH
United BioSource Corporation, London, UK
OBJECTIVES: To investigate whether there is a relationship between the day of the
week patients undergo elective surgery and in-hospital death. METHODS: Retro-
spective analysis of secondary users service data on adjusted odds ratios for in-
hospital death within 30 days of procedure using logistic regression modelling.
Patients in acute and specialist English public hospitals undergoing elective sur-
gery over the financial years 2006 to 2008. RESULTS: There were 15,230 in-hospital
30-day deaths as a consequence of 4,197,761 all elective inpatient surgical admis-
sions (an overall crude mortality rate 3.6 per 1000). The overall adjusted odds of
death for all elective surgical procedures were 33% and respectively 90% higher if
the procedures were carried out on Friday or atWeekend compared to Monday (OR
1.33, 95% CI 1.26-1.41 and respectively OR 1.90, 95% CI 1.75-2.05). This equates to a
figure of over 700 excess annual deaths from elective surgery, based on applying
Monday mortality rates. CONCLUSIONS: The study suggests higher risk of death
for patients who have elective surgical procedures carried out closer to the week-
end, in particular on Friday. Further research is needed to understand the extent to
which the ‘weekday effect’ reflects differences in the quality of surgical care.
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PHARMACOTHERAPY AND ASSOCIATED OUTCOMES IN PEDIATRIC BIPOLAR
DEPRESSION
Bhowmik D1, Chen H1, Aparasu RR1, Rajan S1, Sherer JT1, Perez MO2
1University of Houston, Houston, TX, USA, 2Memorial Park Psychiatry, Houston, TX, USA
OBJECTIVES: To examine medication utilization pattern among Medicaid enrolled
children and adolescents with bipolar depression (BD). METHODS: Medicaid Ana-
lytic eXtract (MAX) data fromNewYork, Illinois, California, and Texas, from 2003 to
2007 was used in the analysis. Bipolar depression patients were identified from
inpatient and outpatient files by using ICD-9CM codes 296.5, 296.2, and 296.3. Uti-
lization of selective serotonin reuptake inhibitors (SSRI) and other antidepressants,
typical and atypical antipsychotics (SGA), and mood stabilizers (MS) (lithium, di-
valproex, oxcarbazepine etc) following a bipolar depression diagnosis was investi-
gated. Prevalence of significant outcomes of the disease, namely depressive (ICD-
9CM: 296.5, 296.2, 296.3) and manic (ICD-9CM: 296.0, 296.1, 296.4, 296.81) switch,
and suicidality (ICD-9CM: E950-E958, V62.84) were also measured after initiation of
pharmacotherapy treatment in the BD cohort. Descriptive analysis using SAS 9.2
was conducted to achieve the study objective. RESULTS: From descriptive analysis
23,113 children and adolescents aged 6-18 years and having a bipolar depression
diagnosis were identified. The most commonly used psychotropic drugs following
bipolar depression were SGA (76.45%), Mood stabilizer (66.05%), SSRI (48.71%), and
other antidepressants (35.58%). The most commonly used psychotropic combina-
tions were SGA-MS (40.40%), SGA-SSRI (12.20%), and SSRI-MS (6.04%). Suicidality
was revealed to be a rare outcome in patient cohort, with frequency of 133 (0.82%)
from outpatient file. Incidence of relapse tomania within 6 weeks of pharmacolog-
ical treatment in the patient cohort came out to be 27 (0.17%) from hospital visits
and 809 (5.01%) from office visits. Relapse to depression episode anytime post
pharmacotherapy was suggested to be common, with 692 (4.28%) inpatient and
11,380 (70.46%) outpatient visitors. CONCLUSIONS: Given current treatment guide-
line for pediatric bipolar disorder does not have any recommendation for bipolar de-
pression, future study is necessary to examine comparative effectiveness of existing
pharmacotherapies used in children and adolescents with bipolar depression.
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EVALUATING OUTCOMES FROM PRENATAL ANTIDEPRESSANT EXPOSURE: A
META-ANALYTIC REVIEW
Shen X, Raisch DW
University of New Mexico College of Pharmacy, Albuquerque, NM, USA
OBJECTIVES: To summarize the literature regarding pregnancy/birth/child devel-
opment outcomes of prenatal antidepressant exposure (PAE). METHODS: A Med-
line search was conducted up to October, 2011, restricted to English and human
literature. The MeSH term “antidepressive agents”, was combined with MeSH
terms for spontaneous abortion(SA), preterm birth(PB), birth weight(BW), small for
gestational age(SGA), or poor child development(PCD). We also searched articles
from reference lists of reviews and included studies. We limited the review to
studies with data analysis focusing on the impact of PAE on the outcomes listed
above. Cochran’s Q statistic was used to test the heterogeneity of the results of
included studies for each outcome.When heterogeneitywas absent, a fixed-effects
model was used to pool the effect estimates. Otherwise, meta-regression was per-
formed to explore the reasons for the observed heterogeneity. Meta-regression is a
regression analysis in which each study is a unit of observation and the effect
estimate is regressed on study characteristics. In this review, study characteristics
including antidepressant class, type of source population, adjustment formaternal
depression, exposure definition, duration and timing, and adjustment for more
than three covariates were examined. RESULTS: Thirty-three studies were in-
cluded (18 on PB, 9 on SA, 19 on BW). SGA and PCDwere excluded fromanalysis due
to the limited number of studies(n6). The test of heterogeneity was significant for
PB andmeta-regression showed that adjusting for more than three covariates was
significantly associated with the reported odds ratio(p0.02). The pooled odds ra-
tio(POR) for PB was 1.39 (95% confidence interval (CI)1.27-1.52) for studies with 3
covariates versus 1.82(95% CI1.43-2.29) for other studies. The POR for SA was
1.63(95% CI1.31-2.04) and the pooled difference in BW between the exposed and
the unexposed was -23.6(95% CI-50.1, 2.9) gram. CONCLUSIONS: The PORs
showed that PAE was associated with PB and SA, but not BW.
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ACNE DRUG THERAPY AND THE DEVELOPMENT OF COMORBID MAJOR
DEPRESSIVE DISORDER IN THE UNITED STATES
Lin HC1, Clodfelter RP1, Lee CH2, Balkrishnan R2, Feldman SR3
1Indiana Univeresity, Bloomington, IN, USA, 2University of Michigan, Ann Arbor, MI, USA,
3Wake Forest University, Winston-Salem, NC, USA
OBJECTIVES: Dermatological disorders are associated with secondary psychiatric
illnesses. In particular, acne carries an increased risk of developing major depres-
sive disorder (MDD) and other psychological comorbidities. The association be-
tween acne drug therapy and the incidence of secondary psychiatric disorders,
however, remains unclear. This study evaluated the effects of drug therapies on
the development of comorbid MDD in acne patients in the United States.
METHODS: A longitudinal retrospective study was conducted using the 2003-2007
MarketScan Medicaid Claims dataset representing 177,333 patients with acne vul-
garis. The Cox proportional-hazard survival analysis was performed to obtain the
hazard ratios (HRs) of MDD development, adjusting age, race, sex, physician spe-
cialty, Charlson Comorbidiy index (CCI), and acne drug treatment. RESULTS: Pa-
tients totalling 11,131 had an MDD occurrence within the study period. White
patients had the highest hazard of MDD incidence among all races (all p0.01).
Comparedwith adult patients, youths and childrenwere less likely to have anMDD
occurrence (HRs0.66 and 0.22, respectively; both p0.01). MDD was less frequent
in patients seen by dermatologists, family physicians, or pediatricians (all p0.01).
Patients whose acne was treated with isotretinoin, oral antibiotics, or topical anti-
biotics were less likely to have an MDD occurrence (HRs0.56, 0.41, and 0.46, re-
spectively; all p0.01). A unit of increase in CCI was associated with a 14% higher
hazard of MDD incidence (p0.01). CONCLUSIONS: The likelihood of MDD occur-
rence in acne patients treated with drug therapy varied with age and race. Consul-
tationwith dermatologists, family physicians, or pediatricianswas associatedwith
a lower hazard of MDD. Drug treatment of acne with isotretinoin, oral antibiotics,
or topical antibiotics was associatedwith a reduced incidence of secondaryMDD in
acne patients, indicating that the treatment of the primary cutaneous indication
may reduce the risk of secondary psychiatric comorbidities.
PMH4
COMPARISON OF RISK ADJUSTMENT METHODS IN PREDICTING HEALTH CARE
EXPENDITURE AMONG CHILDREN WITH ATTENTION DEFICIT/
HYPERACTIVITY DISORDER
Bali V, Johnson ML, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: Pediatric Attention Deficit/Hyperactivity Disorder (ADHD) is associ-
ated with substantial financial burden on families, payers, and society. This study
compared different risk adjustmentmethods in predicting health care expenditure
among children with ADHD. METHODS: This study used data from 2008 Medical
Expenditure Panel Survey (MEPS) involving children from 5-17 years of age with
ADHD. Patients with ADHD were identified using International Classification of
Diseases, ninth revision, Clinical Modification (ICD-9-CM) code of ’314’. Diagnosis
based (D’Hoore version of Charlson comorbidity Index (CCI), Modified Elixhauser
comorbidity Index (MECI) ); pharmacy based (Chronic disease score-1 (CDS-1)); and
Columbia Impairment scale (CIS) were used to risk adjust total healthcare expen-
ditures. Performance of each of the comorbidity measures was compared after
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adjusting for baseline factors (age, sex, race, region, metropolitan statistical area,
family income, and health insurance coverage) using regression model statistics
(adjusted R2). RESULTS: The overall prevalence of pediatric ADHD was 2.47% (n 
5.82 million). Most of the children were boys (68%), White (84%) and had private
health insurance (62%). Overall mean annual expenditure was $ 4145.87. Adjusted
R2 for the baseline model was 0.1130. When different comorbidity measures were
added to the baseline model the adjusted R2 increased to: 0.1230 (CIS), 0.1566
(D’Hoore version of CCI), 0.1534 (MECI), and 0.1372 (CDS-1). Among different com-
binations, a model consisting of patient baseline characteristics, MECI, and CIS
explained the most variation in healthcare expenditure (adjusted R2  0.1618).
CONCLUSIONS: Models that include comorbidity and functional status measures
performs best in risk adjusting health care expenditure in pediatric ADHD. There is
a greater need to evaluate the use of CIS as a potential risk adjustment tool in
mental and behavioral problems.
PMH5
ASSOCIATION BETWEEN SECOND GENERATION ANTIPSYCHOTICS AND
CHANGES IN BODY MASS INDEX IN ADOLESCENTS
Ghate SR1, Porucznik C1, Said Q2, Joy EA1, Hashibe M1, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2University of Arkansas for Medical Sciences, Little
Rock, AR, USA
OBJECTIVES: To assess the association of second-generation antipsychotics pre-
scriptions (SGAs) with changes in body mass index (BMI) among adolescents com-
pared to a randomly selected age and gender matched untreated comparison
group. METHODS: A retrospective cohort study was conducted using an ambula-
tory electronic medical record database between January 2004 and July 2009. Anti-
psychotic naïve (no evidence of SGAs during 540 days pre index period) mono-
therapy adolescents 12–19 years with at least one prescription for any SGA during
395 days follow-up period were eligible. The comparison group without antipsy-
chotic prescription was matched (3:1) to the antipsychotic group based on age,
gender, andmonth of SGA. Amaximum follow-up BMI 90 days post index date was
evaluated and percentage change from baseline BMI was calculated. Multivariate
linear regression was conducted to assess the percent change in follow-up BMI
from baseline among antipsychotic users compared to the comparison group con-
trolling for covariates. RESULTS: The mean age (15.35 years, SD 2.27) and gender
(males, 53%) distribution among the antipsychotic group (n793) was similar
(p0.05) to the comparison group (n2,373). The mean percentage increase in
follow-up BMI from baseline for antipsychotic group was significantly higher than
the comparison group (p0.01) except for ziprasidone (p0.05). After adjusting for
covariates, adolescents on olanzapine had the highest percentage increase in fol-
low-up BMI from baseline (5.84%, 95% Confidence Interval [CI], 4.07–7.61) followed
by aripiprazole (4.36%; 95%CI, 3.08–5.64), risperidone (3.65%; 95%CI, 2.61–4.68), and
quetiapine (1.53%; 95% CI, 0.53–2.52) compared to the comparison group. Normal
weight adolescents on antipsychotics had higher percentage increase in follow-up
BMI from baseline compared to overweight or obese. CONCLUSIONS: Treatment
with SGAs is associated with significant increase in BMI among adolescents rela-
tive to amatched comparison group. Interventions to controlweight gain should be
considered in adolescents treated with SGAs.
PMH6
THE IMPACT OF LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS
ON HOSPITALIZATION RATES IN PATIENTS WITH SCHIZOPHRENIA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Lafeuille MH1, Dean J1, Carter V1, Duh MS2, Fastenau J3, Dirani R3, Lefebvre P1
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3Janssen Scientific Affairs, LLC, Titusville, NJ, USA
OBJECTIVES: To compare, by performing a meta-analysis, the impact of long-acting
injectable antipsychotics (LAIs) versus oral atypical antipsychotics (OAs) on hospital-
izations among schizophrenia patients.METHODS: Using the PubMed database and
major psychiatric conference proceedings, a systematic literature review for January
2000 to June 2011 was performed to identify English-language studies evaluating
schizophrenia patients treated with antipsychotics. Studies reporting hospitalization
rates as a percentage of patients hospitalized or as the number of hospitalizations per
person per year were selected. The primary endpoint for the meta-analysis was per-
centage decrease in hospitalization rates from baseline during treatment. Pooled
treatment-effect estimateswerecalculatedusing random-effectmodels.Meta-regres-
sions adjusted for study-level characteristics to account for the heterogeneity across
studies. A sensitivitymeta-regression analysis estimating the treatment effect on ab-
solute hospitalization rates was also conducted. RESULTS: Fifty-three studies evalu-
ating 81 treatment arms (LAIs  15 arms, 5294 patients; OAs  66 arms, 96,013 pa-
tients) were identified. Reduction in hospitalization rates for LAIswas 24.5 percentage
pointshigher than forOAs (random-effect estimates: LAIs 60.0%vsOAs 35.5%, p
0.018). Based on ameta-regression analysis, controlling for age, sex, refractory schizo-
phrenia, and study characteristics, the adjusted percentage reduction in hospitaliza-
tion rates for LAIs was 36.9 percentage points (adjusted estimates: LAIs  66.4% vs.
OAs 29.5%, p 0.024) higher than forOAs. The sensitivity analysis basedonabsolute
hospitalization rates corroborated these findings (adjustedhospitalization rate during
follow-upwas 12.6% lower for LAIs than for OAs; adjusted estimates: LAIs 13.7% vs.
OAs 26.2%, p 0.033). CONCLUSIONS: Results of this meta-analysis suggest that
LAIs significantly reduce hospitalization rates for schizophrenia patients compared to
OAs.
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IMPACT OF LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS ON
REHOSPITALIZATION RATES AND EMERGENCY ROOM VISITS AMONG
RELAPSED SCHIZOPHRENIA PATIENTS
Lafeuille MH1, Laliberté-Auger F1, Lefebvre P1, Frois C2, Fastenau J3, Duh MS2
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc., Boston, MA, USA,
3Janssen Scientific Affairs, LLC, Titusville, NJ, USA
OBJECTIVES: To compare the impact of switching to long-acting atypical antipsy-
chotic therapy (LAT) versus continuing with oral antipsychotics (APs) on the recur-
rence of hospitalizations and emergency room (ER) visits among schizophrenia
patients who relapsed.METHODS: Hospital discharge and billing records from the
Premier Perspective™ Comparative Hospital Database (2006Q1-2010Q4) were ana-
lyzed. Adult patients receiving oral APs during a schizophrenia-related hospital-
izationwere identified and further stratified upon their next schizophrenia-related
rehospitalization (ie, relapse) into the following exposure groups: 1) patients
switching to LAT (paliperidone palmitate or risperidone) versus 2) patients con-
tinuing with oral APs. LAT relapse patients were matched 1:3 with oral AP relapse
patients using a propensity score model. The Andersen-Gill extension of the Cox
proportional hazardsmodel was used to assess the impact of LAT versus oral AP on
time to multiple recurrences of hospitalizations and ER visits. RESULTS: A total of
1064 LATpatientswerematchedwith 3015 oral AP patients. LAT and oral AP groups
werewell-balancedwith respect to age (42.5 vs. 42.9 years, p0.2859), gender (43.5%
vs. 45.5% female, p0.2429), race, region, payer, hospital characteristics, admitting
diagnoses, physician specialty, and degree of illness severity (P0.05 for all). Over a
mean 30-month follow-up period, LAT patients were associated with significantly
lower rates of all-cause rehospitalizations (1.27 vs. 1.61, p0.0001) and ER visits
(2.36 vs. 2.68, p0.0195) compared with oral AP patients. Based on Andersen-Gill
models, all-cause rehospitalization rates (hazard ratio [HR]0.82, 95%CI: 0.77-0.87,
p0.0001) and ER visits (HR0.89, 95%CI: 0.87-0.94, p0.0001) were significantly
lower for LAT than for oral AP. Consistently significant results were found when
restricting to mental disorder–related events (rehospitalizations: HR0.86, 95%CI:
0.80-0.92, p0.0001; ER visits: HR0.94, 95%CI: 0.89-0.99, p0.042). CONCLUSIONS:
This hospital database analysis found that in relapsing schizophrenia patients,
LATs were associated with lower rehospitalization and ER-visit rates.
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LONG-TERM FOLLOW-UP EFFECTS OF COMPUTERIZED OR INTERNET-BASED
COGNITIVE BEHAVIORAL THERAPY FOR DEPRESSION AND ANXIETY: A META-
ANALYSIS
Bhattacharya R, Kelley G, Bhattacharjee S
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Internet/computer based Cognitive Behavioral Therapies (iCBT/cCBT)
might serve as a cost-effective alternative to face-to-face psychotherapies. The
purpose of this study was to synthesize the quantitative evidence from random-
ized clinical trials (RCTs) addressing the long term benefits of iCBT/cCBT for pa-
tientswith depression and anxiety.METHODS: Previous studies published through
November 2011 were retrieved from three electronic databases (Scopus, Pubmed,
PsycINFO). The inclusion criteria were English-language RCTs involving partici-
pants with major depressive disorder/depressive symptoms, generalized anxiety
disorder, social phobia, and social anxiety disorder. The iCBT/cCBT interventions
were compared to either some other treatment or to no-treatment control groups
that were followed for1 year. Standardized effect sizes (ES) were calculated from
sample sizes, means and standard deviations for the primary outcome measure
that was most closely related to the principal disorder. A random-effects model
was used to calculate pooled effect sizes ES across the studies. Leave-one-out
sensitivity analysis was also performed. RESULTS: Of the 769 articles identified, 82
were considered for full text retrieval and 10 met all inclusion criteria. The pooled
mean ES from the ten different RCTs from 3 different continents showed no statis-
tically significant difference when i-CBT/c-CBT was compared to active control
[Effect Size (ES), - 0.10 , 95% Confidence Interval (CI), -0.21 to 0.01]. In contrast,
results were significant when compared to placebo control (ES, -0.37, 95% CI: -0.70
to -0.05). No significant benefits for i-CBT/c-CBT in the long-termwere found in the
therapist supported subgroup. Results were robust when sensitivity analysis was
performed. CONCLUSIONS: Evidence regarding the long term benefits of i-CBT/c-
CBT for reducing depression and anxiety in adults are weak. Additional well-de-
signed RCTs involving longer follow-up are needed in order to assess the long-tem
effectiveness of this intervention.
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DESCRIPTION OF THE BURDEN ASSOCIATED WITH COGNITION DEFICITS IN
SCHIZOPHRENIA
Millier A1, Aballea S1, Toumi M2, Azorin JM3
1Creativ-Ceutical, Paris, France, 2University Claude Bernard Lyon1, Lyon, France, 3CHU de
Marseille, Marseille , France
OBJECTIVES: Schizophrenia is often associated with cognitive deficits (CD). This cov-
ers diverse domains such as learning,memory and language. Cognitive skills arewell-
known predictors of social functioning, and knowledge of outcomes associated to CD
is necessary to develop effective treatment strategies. The purpose of this study is to
describe the schizophrenic population with CD.METHODS:Weworked on data from
the EuroSC cohort (N288 in France, N618 in Germany andN302 in UK). Definition
of CD was based on the cognition subscore of Positive and Negative Syndrome Scale
(PANSS). Patientswith a score lower than themedian of the overall setwere identified
at baseline. As five assessments were performed over 2 years, pathways of patients
with CD were explored. Bivariate analyses were conducted to compare patients with
CD to others in terms of quality of life, functioning, side effects and depression.
RESULTS: On the overall set, mean cognition subscore was 9.67 (SD4.60, Me-
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